Fas promoter-670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus

초록

Objective. To evaluate whether the polymorphism of Fas promoter -670 is associated with susceptibility to systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and their clinical features. Methods. A polymerase chain reaction of a genomic DNA-restriction fragment length polymorphism was used to determine genotypes of the Fas promoter -670 in 87 patients with SLE, 87 with RA, and 87 healthy controls. A second cohort of SLE patients (n=85) was included. Clinical manifestations were analyzed in each patient and correlated with the genotypes. Results. The genotype distribution of the Fas promoter -670 did not differ between patients with SLE and control subjects (AA. GA, GG genotypes 31. 54, 15% vs 30, 55, 15% controls. respectively: chi-squared = 0.03, 2 df, p=0.99) and between RA patients and controls (AA, GA, GG genotypes 38, 44, 18% vs 30, 55, 15% controls, respectively, chi-squared = 2.30, 2 df, p=0.32). Regarding the clinical status of lupus patients according to Fas promoter -670 genotypes, there was no significant difference in age at onset, anti-dsDNA titer, C3, C4 level. renal involvement. number of American College of Rheumatology (ACR) criteria met, SLE Disease Activity Index, SLE International Collaborating Clinics/ACR Damage Index, or autoantibody profiles. However, the frequency of anti-RNP antibody was significantly different in the AA, GA, and GG groups (71, 25, 30%; chi-squared = 13.29. 2 df, p=0.001). To confirm this finding, the Fas promoter -670 genotype was examined in a second cohort of SLE patients (n=85). The result in the second cohort replicated the association shown in the first. In patients with RA, there was no significant difference in clinical and laboratory findings according to the Fas promoter -670 genotypes. Conclusion. Our data suggest that the Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in SLE.

키워드